PubMed

Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.

Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H; European HIV Cohorts.

Ann Intern Med. 2002 Aug 20;137(4):239-50.PMID: 12186514 [PubMed - indexed for MEDLINE]Related articlesFree article

Summaries for patients. Can maintenance therapy for opportunistic infections in HIV-infected people be stopped safely?

[No authors listed]

Ann Intern Med. 2002 Aug 20;137(4):I34. No abstract available. PMID: 12186538 [PubMed - indexed for MEDLINE]Related articlesFree article

Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy.

Rossi M, Flepp M, Telenti A, Schiffer V, Egloff N, Bucher H, Vernazza P, Bernasconi E, Weber R, Rickenbach M, Furrer H; Swiss HIV Cohort Study.

Swiss Med Wkly. 2001 Aug 11;131(31-32):471-7.PMID: 11641970 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD; Eight European Study Groups.

N Engl J Med. 2001 Jan 18;344(3):168-74.PMID: 11188837 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA.

Ann Intern Med. 2000 Oct 3;133(7):493-503.PMID: 11015162 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, Podzamczer D, Alberdi JC, Martínez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E; Grupo de Estudio del SIDA 04/98.

N Engl J Med. 2001 Jan 18;344(3):159-67.PMID: 11172138 [PubMed - indexed for MEDLINE]Related articlesFree article

Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.

Shafran SD, Mashinter LD, Phillips P, Lalonde RG, Gill MJ, Walmsley SL, Toma E, Conway B, Fong IW, Rachlis AR, Williams KE, Garber GE, Schlech WF, Smaill F, Pradier C.

Ann Intern Med. 2002 Nov 5;137(9):734-7.PMID: 12416943 [PubMed - indexed for MEDLINE]Related articlesFree article

Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.

Lazaro E, Coureau G, Guedj J, Blanco P, Pellegrin I, Commenges D, Dabis F, Moreau JF, Pellegrin JL, Thiébaut R; ANRS Co3 Aquitaine Cohort.

Antivir Ther. 2006;11(3):343-50.PMID: 16759051 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study.

Furrer H, Telenti A, Rossi M, Ledergerber B.

AIDS. 2000 Jul 7;14(10):1409-12.PMID: 10930156 [PubMed - indexed for MEDLINE]Related articles

The cost-effectiveness of preventing AIDS-related opportunistic infections.

Freedberg KA, Scharfstein JA, Seage GR 3rd, Losina E, Weinstein MC, Craven DE, Paltiel AD.

JAMA. 1998 Jan 14;279(2):130-6. Erratum in: JAMA 1999 Jun 2;281(21):1989. PMID: 9440663 [PubMed - indexed for MEDLINE]Related articlesFree article

Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.

Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D.

AIDS. 2000 May 26;14(8):1041-9.PMID: 10853987 [PubMed - indexed for MEDLINE]Related articles

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.PMID: 10605973 [PubMed - indexed for MEDLINE]Related articlesFree article

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J.

AIDS. 1999 Sep 10;13(13):1647-51.PMID: 10509565 [PubMed - indexed for MEDLINE]Related articles

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.

Jouan M, Savès M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, Fillet AM, Nciri M, Sénéchal B, Chêne G, Tural C, Lasry S, Autran B, Katlama C; RESTIMOP study team.

AIDS. 2001 Jan 5;15(1):23-31.PMID: 11192865 [PubMed - indexed for MEDLINE]Related articles

A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.

Green H, Hay P, Dunn DT, McCormack S; STOPIT Investigators.

HIV Med. 2004 Jul;5(4):278-83.PMID: 15236617 [PubMed - indexed for MEDLINE]Related articles

Natural history of opportunistic disease in an HIV-infected urban clinical cohort.

Moore RD, Chaisson RE.

Ann Intern Med. 1996 Apr 1;124(7):633-42.PMID: 8607591 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.

Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza PL, Rickenbach M, Flepp M, Malinverni R.

N Engl J Med. 1999 Apr 29;340(17):1301-6.PMID: 10219064 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.

Verbraak FD, Boom R, Wertheim-van Dillen PM, van den Horn GJ, Kijlstra A, de Smet MD.

Br J Ophthalmol. 1999 Oct;83(10):1186-9.PMID: 10502584 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.

Zeller V, Truffot C, Agher R, Bossi P, Tubiana R, Caumes E, Jouan M, Bricaire F, Katlama C.

Clin Infect Dis. 2002 Mar 1;34(5):662-7. Epub 2002 Jan 24.PMID: 11810599 [PubMed - indexed for MEDLINE]Related articles

Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.

Dankner WM, Lindsey JC, Levin MJ; Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327.

Pediatr Infect Dis J. 2001 Jan;20(1):40-8.PMID: 11176565 [PubMed - indexed for MEDLINE]Related articles